In the study by Tarkun et al., in the MPN group, serum GDF15 levels were detected to be significantly high; however, no difference was detected in serum hepcidin levels of MPN patients when compared to the control group. This evidence concerns the gene GDF15 and myeloproliferative neoplasm.